The J-ALEX trial-is frontline alectinib a new standard of care?

Affiliations

Editorial

Jeffrey Zweig et al. J Thorac Dis. 2017 Aug.

. 2017 Aug;9(8):2242-2245.

doi: 10.21037/jtd.2017.06.134.

¹ Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Hida T, et al. Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.

1. 1. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 5. 2017). Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
1. Felip E, Bauer T, Solomon B, et al. Safety and efficacy of lorlatinib (PF-06463922) in patients with advanced ALK+ or ROS1+ non-small-cell lung cancer (NSCLC). J Thorac Oncol 2017;12:S383-4. 10.1016/j.jtho.2016.11.433 - DOI
1. Reckamp KL, Wakelee HA, Patel S, et al. CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts). J Thorac Oncol 2017;28: ii28-ii51.
1. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77. 10.1056/NEJMoa1408440 - DOI - PubMed
1. Soria JC, Tan DS, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389:917-29. 10.1016/S0140-6736(17)30123-X - DOI - PubMed